1285539-74-3

1285539-74-3 structure

Name: Febuxostat-d7
Chemical Name: 2-(3-Cyano-4-{[2-(2H3)methyl(2,3,3,3-2H4)propyl]oxy}phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid
CAS Number: 1285539-74-3
Molecular Formula: C₁₆H₉D₇N₂O₃S
Molecular Weight: 323.42
Catalog: Signaling Pathways Metabolic Enzyme/Protease Xanthine Oxidase
Create Date: 2018-06-02 16:35:44
Modify Date: 2025-08-24 17:59:20
Febuxostat-d7 is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is selective xanthine oxidase inhibitor with a Ki of 0.6 nM[1].

Name	2-(3-Cyano-4-{[2-(2H3)methyl(2,3,3,3-2H4)propyl]oxy}phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid
Synonyms	2-(3-Cyano-4-{[2-(2H3)methyl(2,3,3,3-2H4)propyl]oxy}phenyl)-4-methyl-1,3-thiazole-5-carboxylic acid 5-Thiazolecarboxylic acid, 2-[3-cyano-4-[[2-(methyl-d3)propyl-2,3,3,3-d4]oxy]phenyl]-4-methyl-

Description	Febuxostat-d7 is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is selective xanthine oxidase inhibitor with a Ki of 0.6 nM[1].
Related Catalog	Research Areas >> Cancer Research Areas >> Metabolic Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Xanthine Oxidase
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Takano Y, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci, 2005, 76(16), 1835-1847. [3]. Sanchez-Lozada LG, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol, 2008, 294(4), F710-F718. [4]. Sanchez-Lozada LG, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol, 2008, 108(4), p69-p78. [5]. Xu X, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. Card Fail, 2008, 14(9), 746-753.